Divi's Laboratories has witnessed a remarkable surge in its stock price, hitting a fresh 52-week high as of November 9, 2026, following the release of its robust second-quarter earnings for FY27. The [pharmaceutical](/topic/healthcare-pharma) giant reported a staggering 64% year-on-year increase in net profit, amounting to ₹1,127 crore, while revenue soared by 35% to ₹3,676 crore. This impressive performance has prompted a flurry of positive commentary from brokerages, highlighting the company's growth potential in custom synthesis and peptide manufacturing.
Record High Performance Amid Strong Earnings
On November 9, 2026, Divi's Laboratories shares rallied over 6%, marking the second consecutive day of hitting a new 52-week high. This surge followed an 8% increase during the special [Muhurat Trading](/muhurat-trading-2026-top-stock-picks-with-upside-potential-up-to-54) session the previous day. The strong quarterly results have bolstered investor confidence, with many brokerages revising their ratings and target prices for the stock.
The company reported a foreign exchange gain of ₹24 crore during the quarter, down from ₹63 crore in the same period last year. Despite this decline, the overall financial performance has been robust, with the custom synthesis segment emerging as a key growth driver.
Brokerages Weigh In: Buy, Sell, or Hold?
Following the announcement of its Q2 results, several brokerages have provided insights into the future of Divi's Laboratories stock. Nuvama Institutional Equities has maintained a 'BUY' rating, citing the company's promising opportunities in peptide manufacturing. They noted the installation of 3,000-litre solid-phase peptide synthesis (SPPS) lines, which positions Divi's for significant growth over the next two to three years. Nuvama has raised its valuation multiple for Divi's to 44 times EV/EBITDA from 40 times and increased its target price to ₹12,000 from ₹9,600.
Motilal Oswal Financial Services has also raised its earnings estimates for Divi's by 21% for FY27 and 19% for FY28. Their analysis indicates that the company is well-positioned to secure business from large innovator customers, supported by its scientific capabilities across various segments. However, they have maintained a 'NEUTRAL' rating, citing limited upside at current valuations, with a target price of ₹11,110.
Goldman Sachs has echoed a positive sentiment, retaining its 'BUY' rating with a target price of ₹11,700 per share. The brokerage highlighted that revenue and EBITDA grew by 35% and 76% year-on-year, respectively, surpassing their expectations. They noted that the custom synthesis business was a key growth driver, recording a 54% YoY expansion, significantly exceeding their estimate of 34%.
Custom Synthesis and Peptide Manufacturing: The Growth Engines
Divi's Laboratories has strategically focused on expanding its custom synthesis and peptide manufacturing capabilities, which have become critical to its growth strategy. The company's efforts in innovation-led peptides and the installation of advanced SPPS lines are expected to enhance its production capacity significantly. Nuvama's report indicates that several peptide fragments are currently undergoing validation, which could further strengthen Divi's position in this lucrative market.
Motilal Oswal's analysis suggests that Divi's is poised to deliver impressive compound annual growth rates (CAGR) of 23% in revenue, 34% in EBITDA, and 33% in profit after tax (PAT) over the FY26–FY28 period. This growth is attributed to the increasing contribution from projects progressing towards validation and commercialization, as well as an improved outlook for the generics and nutraceuticals businesses.
Financial Metrics and Future Outlook
The following table summarizes key financial metrics for Divi's Laboratories following the Q2 FY27 results:
| Metric | Q2 FY27 | YoY Change |
|---|---|---|
| Net Profit | ₹1,127 crore | +64% |
| Revenue | ₹3,676 crore | +35% |
| EBITDA Margin | 42.6% | +989 bps |
| Custom Synthesis Growth | 54% | - |
| Target Price (Nuvama) | ₹12,000 | - |
| Target Price (Goldman) | ₹11,700 | - |
Conclusion: Navigating the Investment Landscape
As Divi's Laboratories continues to demonstrate strong financial performance and growth potential, investors are faced with critical decisions regarding their positions in the stock. With brokerages divided on their ratings, the outlook for Divi's remains promising, particularly in light of its advancements in custom synthesis and peptide manufacturing. Investors must weigh the potential for further growth against current valuations as they consider whether to buy, sell, or hold their shares in this dynamic pharmaceutical company.
